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postdischarge cost, the total cost, and the economic burden of
community-acquired pneumonia among patients aged 19 years or
older in the Philippines and 2) the difference between the estimated
costs and the Philippine Health Insurance Corporation (PhilHealth)
pneumonia case rate payments. Methods: The study involved two
tertiary private hospitals in the Philippines. Using the societal per-
spective, both health care and non–health care costs were deter-
mined. A base-case analysis and sensitivity analyses were performed,
and the economic burden of pneumonia was determined using
PhilHealth claims. Results: The estimated cost of hospitalization for
community-acquired pneumonia-moderate risk (CAP-MR) ranged
from Philippine peso (PHP) 36,153 to 113,633 (US $852–2678) and its
1-week postdischarge cost ranged from PHP1450 to 8800 (US $34–207).
The cost of hospitalization for community-acquired pneumonia-high
risk (CAP-HR) ranged from PHP104,544 to 249,695 (US $2464–5885)
and PHP101,248 to 243, 495 (US $2386–5739) using invasive andee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.03.003
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nila, Philippines.noninvasive ventilation, respectively. The postdischarge cost for CAP-
HR ranged from PHP1716 to 10,529 (US $40–248). If only health care cost
was considered, the cost ranged from PHP24,403 to 89,433 for CAP-MR
and PHP92,848 to 213,395 for CAP-HR. The present PhilHealth case rate
payments are PHP15,000 (US $354) and PHP32,000 (US $754) for CAP-MR
and CAP-HR, respectively. Based on the number of PhilHealth claims
for 2012 and the estimated health care cost, the economic burden of
pneumonia in 2012 was PHP8.48 billion for CAP-MR and PHP643.76
million for CAP-HR. Conclusions: The estimated health care cost of
hospitalization is markedly higher than the PhilHealth case rate pay-
ments. As per the study results, the economic burden of pneumonia is,
thus, signiﬁcantly higher than PhilHealth estimates.
Keywords: case rate payments, economic burden, PhilHealth,
Philippines, pneumonia.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In 2009, pneumonia was the fourth leading cause of mortality in
the Phillipines, occurring in about 46 for every 100,000 Filipinos
[1]. Moreover, together with acute lower respiratory tract infec-
tions, it was the second highest cause of morbidity, with a rate of
about 613 per 100,000 Filipinos in the same year [2].
For the year 2010, the Philippine National Health Insurance
(PhilHealth) reported pneumonia (age not speciﬁed) as the num-
ber one illness on the basis of the number of claims (295,390
claims), which amounted to Philippine peso (PHP) 2,042,400,000
[3]. This amount was also the highest among the top 20 illnessesreimbursed by PhilHealth in that time period [3]. Likewise, for the
ﬁrst three quarters of 2011, it ranked ﬁrst among the top 20
illnesses reimbursed by PhilHealth on the basis of the amount of
claims (PHP1,851,900,000), although it ranked only second for the
same period of time on the basis of the number of claims
(262,320) [4].
In view of the above prevalence of pneumonia in a country
with scarce resources, it is imperative to determine its economic
burden. PhilHealth reimburses hospitals for hospitalized pneu-
monia cases on the basis of its mandated case rate payments
since September 1, 2011 [5]. How this case rate payment approx-
imates the real cost of hospitalization for pneumonia is a veryociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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rtment of Internal Medicine, Manila Doctors Hospital, 667 United
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but also by other stakeholders especially the policymakers.
Hence, this study had the following objectives.
Objectives
General objective
To determine the economic burden of community-acquired
pneumonia among adults (aged Z 19 years) using the societal
perspective.
Speciﬁc objectives1. To determine the cost of treating pneumonia as follows:
a. Cost of hospitalization
b. Total cost (hospitalization cost þ 1-week postdischarge
cost)
2. To estimate the difference between the above cost of hospital-
ization and that of the PhilHealth pneumonia package
3. To estimate the economic burden of community-acquired
pneumonia in the country.
Methods
Setting
The above objectives were determined using the setting of an
urban area and a suburban area in the country. The study sites
were two tertiary private hospitals, the ﬁrst one located in
Manila, an urban area and the capital of the Philippines, while
the other was located in a suburban area approximately 30 km
south of Manila.
Inclusion Criteria
The study included patients aged 19 years and older who were
admitted with a diagnosis of pneumonia on the basis of clinical
signs and symptoms, radiologic test, and microbiology from
January to December 2012 in the above tertiary hospitals. The
medical records of the patients who satisﬁed the inclusion
criteria were reviewed, after which the corresponding data were
recorded.
Design: Cost Analysis Using the Societal Perspective
In any costing study, the steps involved are identiﬁcation,
measurement, and valuation of costs. These were done for both
hospitalization and postdischarge costs. Drummond’s classiﬁca-
tion of costs was used, which are 1) cost of health care resources
consumed, 2) cost of patient/patient’s family resources or out-of-
pocket expenses, (3) productivity or production losses, and 4) cost
due to the consumption of other resources/sectors [6].
The reference time used for the ﬁnal cost was that for the year
2012 to coincide with the time period of hospitalization of the
included patients.
Moreover, 2012 was also the reference year for the other types
of costs (productivity losses and the cost for the consumption of
other resources). Adjustment of the cost to 2012 was done
through the use of consumer price indices.
All the above categories of costs were used for the determi-
nation of the economic burden of pneumonia except for the ﬁrst
one because this category refers to the cost of establishing and
maintaining a health care program or service and the costs of
treating the possible adverse effects of the said program. Under
this category are ﬁxed and variable costs (rent or capital cost and
supplies). This type of cost was excluded because there was no
need to establish a new facility or health care program. The studysettings are already equipped with provisions for the diagnosis
and treatment of pneumonia.
Hospitalization Costs
The cost of hospitalization refers to the costs incurred for hospital
conﬁnement for pneumonia, that is, in-patient hospitalization. In
estimating the hospitalization costs, the following identiﬁed cost
centers were measured and valued:1. Out-of-pocket expenses, which included the following:
a. Emergency room fees: cost of care delivered at the
emergency room.
b. Cost of diagnostic examinations: cost of laboratory exami-
nations, x-rays, and so forth.
c. Treatment cost: cost of medications, intravenous ﬂuids,
and other related expenses such as nebulizations and
oxygenation.
d. Room and board (accommodations).
e. Supplies.
f. Professional fees.2. Production/productivity losses
Production losses have been deﬁned as “wealth lost to society
due to disease” [7], while the United States Panel on Cost
Effectiveness in Health and Medicine uses the term “produc-
tivity losses” to refer to “the costs associated with lost or
impaired ability to work or to engage in leisure activities due
to morbidity and lost economic productivity due to death” [6].
These costs were used to refer to the loss of income incurred
by the patient or patient’s relative or companion while in the
hospital on the assumption that either is gainfully employed.
Variations exist with regard to the valuation of productivity
costs. For this article, “labor productivity,” deﬁned by the
Organization for Economic Cooperation and Development as
“the ratio of a volume measure of output to a volume measure
of input,” was used [8]. Thus, labor productivity was computed
by dividing the gross domestic product (GDP), the output, by
the number of employed persons, the input. “GDP refers to the
value of all goods and services produced domestically; the
sum of gross value added of all resident institutional units
engaged in production” [8].
The Philippines 2012 GDP was divided by the number of
employed persons in the same year to come up with the
productivity losses for 2012. The labor force survey was used
as the source for the number of employed persons for the
same year [9].3. Cost due to the consumption of other resources
The last category of cost refers to the cost due to the
consumption of other resources or other sectors. This
includes the cost of volunteer work or costs incurred by the
patient’s relative while attending to the needs of the patient.
The cost of production losses incurred by the relative who
took care of the patient may be considered under this cost, but
to prevent double counting this cost was covered under
production losses (mentioned earlier). However, other costs
such as costs of transportation and meals incurred by the
patient’s relative during the course of hospitalization were
included under this last type of cost.
The average cost of three meals per day and snacks (from the
respective hospital canteens) and a conservative estimate of
transportation cost of about PHP100/d (using public trans-
portation) multiplied by the duration of hospitalization
(average number of hospitalization days as mentioned in the
earlier section of the study) were used.The out-of-pocket expenses constituted the health care cost,
whereas the sum of the productivity losses and the cost of
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 1 1 8 – 1 2 5120consumption of other resources constituted the non–health care
costs for hospitalization.
Postdischarge and Follow-Up Costs
Follow-up costs entailed identiﬁcation of the three types of costs
that were mentioned earlier. In this time period, out-of-pocket
expenses covered the costs of medications after discharge.
No additional laboratory examinations were identiﬁed during
the follow-up period (1 week postdischarge).
Moreover, it was assumed that a relative or another person
accompanied the patient during the follow-up visit and hence he
or she had to absent himself or herself from work. It was
estimated that the actual loss of productivity was about 4 hours
or half a day of regular working time (inclusive of the time to go
to and from the doctor’s clinic and the waiting time before the
actual consultation and the actual consultation time). Many
relatives or the accompanying person, however, do not report
for work anymore after bringing the patient home; hence, the
actual productivity loss was computed for one whole day.
The cost of consumption of other resources covered the
transportation expenses and snacks for the follow-up visit of
both the patient and his or her companion.
Base-Case Analysis and Sensitivity Analyses
The most recent local clinical practice guidelines [10] and usual/
standard practice patterns were used as reference for the costing
of the diagnostic procedures and therapeutic interventions.
It should be recognized that differences exist between the
terms “cost” and “charges/prices”; however, in this study they
were used synonymously because no standard cost exists in the
items identiﬁed for costing. In addition, these charges/prices
were the ones paid through out-of-pocket.
The hospital charges for diagnostic procedures, room and
board, ventilation use, and other relative charges of the included
study sites were used.
However, to decrease variability in the cost of medications
brought about by differences in hospital prices of such, the cost of
medications was based on the prices obtained from the biggest
drugstore chain in the country. Prices from this drugstore chain
approximate the real out-of-pocket expenses better than do
international prices or wholesale acquisition costs recommended
by other studies [11,12]. Moreover, this drugstore chain has a
nationwide presence and controls about 80% of the retail phar-
maceutical market [8].
A base-case analysis whereby the scenario of having lowest
costs of the range of values of the identiﬁed cost centers was
used. In terms of the cost of medicines, this meant that the cost
of the generic counterpart (marketed under the generic name
with the name of the company or another brand given by the
manufacturer to distinguish it from other generic medications)
rather than the innovator brand of the recommended medicine
was used. Also, lowest charges for diagnostic examinations, room
accommodation, and other identiﬁed cost centers were used for
the base-case analysis. Last, the average duration of hospital-
ization was used in the base-case analysis.
However, because of variability in costs, several scenarios
were considered for sensitivity analyses on the basis of differ-
ences in the following factors:1. Antibiotics used: For community-acquired pneumonia-mod-
erate risk (CAP-MR), the cost of the combination of macrolide
with Co-Amoxiclav, cefuroxime, or ceftriaxone was analyzed.
For community-acquired pneumonia-moderate risk (CAP-HR),
the cost of piperacillin/tazobactam plus azithromycin and
meropenem plus levoﬂoxacin was computed. These antibiotic
regimens were the ones included in the cost analysis becausethey were the treatment recommendations given by the local
clinical practice guidelines for pneumonia [10]. The costs of
these antibiotics were determined using the most expensive
brand (the innovator brand) for sensitivity analyses in con-
trast with the lower or lowest priced brand or generic counter-
parts used for the base-case analysis.2. Type of accommodations: either ward or private room.
3. Duration of hospital days: average duration plus 1 SD.
4. Location of the hospital where the patient was conﬁned:
either hospital A or B.
5. Variations in the professional fees.
6. Type of ventilation used (for CAP-HR).
Economic Burden of Pneumonia
The economic burden of pneumonia requiring hospitalization,
that is, those classiﬁed by PhilHealth as CAP-MR and CAP-HR,
was estimated using the health care cost of hospitalization as
computed in the preceding sections multiplied by the corre-
sponding number of PhilHealth claims/reimbursements for
CAP-MR and CAP-HR in 2012. This was compared with PhilHealth
case rate payments, also multiplied by the corresponding number
of PhilHealth claims for CAP-MR and CAP-HR in 2012.Results
Using the societal perspective, the cost of hospitalization for CAP-
MR and CAP-HR was obtained. Although many patients had
concomitant conditions such as hypertension and diabetes, the
analysis dealt only with the cost for pneumonia.
For CAP-MR, the costs (obtained during the data collection
period, i.e., fourth quarter of 2013 to the ﬁrst quarter of 2014) for
the above scenarios exclusive of the professional fees are sum-
marized in Table 1.
The professional fee mandated by PhilHealth for CAP-MR is
PHP4500, which corresponds to 30% of the case rate payment of
PHP15,000 for CAP-MR [5]. In contrast, in the “real-world sce-
nario,” professional fees vary considerably because of several
factors, for example, the type of accommodation, length of
hospital stay, and difﬁculties encountered in the management
(especially in the presence of comorbid conditions). For this
study, the PhilHealth case rate payment was used for the base-
case scenario (lowest professional fees) and the private room rate
multiplied by the longer duration of days (average plus 1 SD) was
used as the professional fee in sensitivity analyses. The 20%
discount rate for senior citizens (those 60 years and older) was
deducted from the higher professional fee rate because the mean
age of the patients included in the study was 65 years.
However, because the total costs given in Table 1 were based
on nominal prices during the last quarter of 2013 to the ﬁrst
quarter of 2014, these were adjusted to real prices with 2012 as
the base year as explained in the Methods section.
For the year 2012, the GDP of the country was US $250.27
billion [13], with 37.6 million Filipinos employed during that time
[9]. Based on these data and the number of estimated working
days in 2012, the production losses were estimated to be US
$22.50/d or about PHP950.00/d (based on the conversion rate of US
$1.00 to PHP42.43 at that time) [14]. In the local setting, at least
one person (usually a relative) is always present in the patient’s
room to attend to the patient’s other needs while he or she is
conﬁned in the hospital. If both the patient and his or her
companion/relative are economically productive, the production
loss per day was multiplied by 2 to account for the patient’s and
his or her companion’s productivity loss. For the base-case
scenario (lowest production losses), the patient was assumed to
be not economically productive and only his or her companion
was assumed to be economically productive.
Table 1 – Out-of-pocket expenses (health care cost) (PHP) for CAP-MR.
Subtotals (without
PF)
Hospital A: Duration
of hospitalization ¼
4.5 d (average)
Hospital A: Duration
of hospitalization ¼
8 d (average þ 1 SD)
Hospital B: Duration
of hospitalization ¼
6 d (average)
Hospital B: Duration
of hospitalization ¼
10 d (average þ 1 SD)
Co-Amoxiclav þ azithromycin regimen
Ward: lower cost;
expensive brand
31,021; 31,341 33,781; 34,101 20,951; 21,271 27,839; 28,159
Private room; lower
cost; expensive
brand
44,450; 44,771 55,650; 55,971 32,189; 32,509 39,189; 39,509
Cefuroxime þ clarithromycin regimen
Ward: lower;
expensive brand
32,099; 47,110 34,859; 49,870 22,028; 37,040 28,917; 43,928
Private room: lower;
expensive brand
45,528; 60,540 56,728; 71,740 33,267; 48,278 40,267; 55,278
Ceftriaxone þ azithromycin regimen
Ward: low; expensive
brand
32,991; 41,059 35,751; 43,819 22,921; 30,989 29,809; 37,877
Private room: low;
expensive brand
46,421; 54,489 35,751; 43,819 34,159; 42,227 41,159; 49,227
CAP-MR, community-acquired pneumonia-moderate risk; PF, professional Fees; PHP, Philippine peso.
Table 2 – Cost of hospitalization (PHP) for CAP-MR.*
Cost Hospital A Hospital B
Out-of pocket expenses
Subtotal exclusive of PF 29,470–68,153 19,903–52,514
PF 4,500–21,280 4,500–12,160
Production losses 11,400–19,000 9,500–15,200
Cost of consumption of
other resources
3,120–5,200 2,250–3,600
Total cost 48,490–113,633 36,153–83,474
CAP-MR, community-acquired pneumonia-moderate risk; PHP,
Philippine peso.
* Real prices, base year ¼ 2012.
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and his or her companion were assumed to be economically
productive.
The last category of cost can also be considered as out-of-
pocket expenses; however, this was placed in another category to
distinguish it from other expenses included in the section on out-
of-pocket expenses. As mentioned in the Methods section, this
refers to expenses attributed to meals and transportation of the
patient’s companion during the patient’s hospitalization. Table 2
presents all the costs under each category and the total hospital-
ization costs (real cost as of December 2012) for CAP-MR. The
range represents the lowest (base-case analysis) to the higher
(sensitivity analyses) costs.
For CAP-HR, the cost of the antibiotic regimen piperacillin/
tazobactam plus a macrolide (azithromycin) and imipenem
(meropenem) plus a ﬂuoroquinolone (levoﬂoxacin) ranged from
PHP34,307 to 36,316 and PHP56,897 to 92,694, respectively. The
lower cost corresponds to the cost of the generic counterpart,
whereas the higher cost corresponds to the cost of the
innovator brand.
The cost of ventilation took into consideration the type of
ventilation used, that is, either invasive or noninvasive ventila-
tion. With the assumption that the patient stayed in the inten-
sive care unit for 4 days, the cost of ventilation ranged from
PHP20,021 to 30,136 and PHP16,551 to 29,986 for invasive and
noninvasive ventilation, respectively.
Similar to the computation for CAP-MR, the table on out-of-
pocket expenses (Table 3) did not include professional fees. The
total cost of hospitalization for CAP-HR using either of the two
antibiotic regimens and whether invasive or noninvasive venti-
lation was used is given in Table 4. To simplify the models, the
included scenarios were those of the patient’s transfer from the
intensive care unit to a private room.
Fig. 1A,B shows the costs of hospitalization for CAP-MR and
CAP-HR, using the societal perspective, whether inclusive or
exclusive of non–health care costs. PhilHealth case rate payments
(PHP15,000 for CAP-MR and PHP32,000 for CAP-HR) were con-
trasted with values exclusive of non–health care costs because
PhilHealth is concerned only with health care costs.
The postdischarge costs are given in Table 5. These included
out-of-pocket expenses, production losses, and the cost of con-
sumption of other resources. The out-of-pocket expenses referredto the outpatient consultation charge, the lowest of which
corresponded to the private health insurance or health main-
tenance organization outpatient rate.
The postdischarge cost for CAP-HR was almost similar to the
postdischarge cost for CAP-MR, except for the additional cost of
step-down antibiotics (oral form), which were recommended to
be given for an additional 7 days after the completion of the
intravenous (IV) antibiotics course. Three recommended oral
antibiotic regimens were priced (for both the more expensive
and the cheaper available generic counterparts) and added to
out-pocket expenses. These were levoﬂoxacin 750 mg once a day,
ciproﬂoxacin 500 mg twice a day, and ceﬁxime 400 mg once a day,
which were all given for 7 days.
The cost was PHP280 (PHP266 if adjusted to 2012 real prices)
for the 1-week course of the generic ciproﬂoxacin and PHP1820
for the 1-week course of the generic levoﬂoxacin (P1729, real cost
as of 2012). For some patients who stayed in the hospital for more
than 7 days, these step-down antibiotics were already started;
hence, their cost should be included in their hospitalization cost.
However, to segregate the cost of IV antibiotics from the cost of
oral antibiotics, they were all included in the postdischarge cost.
Review of charts of patients admitted in the study setting for
the year 2012 showed that the cost of hospitalization was paid
out of pocket in 69% of the cases while a quarter had a private
health insurance (see Table 6). Although in 6% of the cases,
payments were made through the company where the patient or
Table 3 – Out-of-pocket expenses (health care cost) (PHP) for CAP-HR.
Subtotals Hospital A:
HD ¼ 7.5 d
Hospital A:
HD ¼ 14.5 d
Hospital B:
HD ¼ 5.5 d
Hospital B:
HD ¼ 11 d
A. Invasive ventilation
Piperacillin/tazobactam plus azithromycin 111,280–113,289 130,880–132,889 91,099–93,108 99,099–101,108
Meropenem plus levoﬂoxacin 133,870–169,667 153,470–189,267 113,689–149,486 121,689–157,486
B. Noninvasive ventilation
Piperacillin/tazobactam plus azithromycin 104,753–106,762 124,353–126,362 87,629–89,638 95,629–97,638
Meropenem plus levoﬂoxacin 127,343–163,140 146,943–182,740 110,219–146,016 118,219–154,016
CAP-HR, community-acquired pneumonia-high risk; HD, Hospitalization Days; PHP, Philippine peso.
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the hospital cost will be paid later by the employee through
salary deduction (except for a few instances in which the
company shoulders the entire hospitalization cost).
PhilHealth coverage was availed by patients classiﬁed under
any of the above type of payments, most especially those with
private health insurance or patients who are employed or depend-
ents of employed family members. As of December 31, 2012,
PhilHealth estimated that its registered members and dependents
were approximately 84% of the country’s projected population [15].
Economic Burden of CAP-MR and CAP-HR
As per PhilHealth statistics, in 2012, there were 347,653 Phil-
Health claims for CAP-MR amounting to PHP5.21 billion (PHP5,
214,795,000 under the case rate payment for CAP-MR). For CAP-
HR, there were 7153 claims amounting to PHP228.9 million [15].
Even if the study estimates on the lowest health care costs were
used, the economic burden for CAP-MR would be PHP8.48 billion
and that for CAP-HR would be PHP643.76 million.Discussion
The study has shown the huge economic burden of community-
acquired pneumonia, speciﬁcally those that were classiﬁed asTable 4 – Cost of hospitalization (PHP) for CAP-HR.*
Cost Hospital A Hospital B
Out-of-pocket expenses
A. Invasive ventilation
Subtotal exclusive
of PF
105,716–179,803 86,544–149,612
PF 9,600–33,592 9,600–19,152
B. Noninvasive
ventilation
Subtotal exclusive
of PF
99,516–173,603 83,248–146,315
PF 9,600–33,592 9,600–19,152
Production losses 7,600–28,500 5,700–20,900
Cost of consumption of
other resources
4,160–7,800 2,700–4,950
Total cost: Invasive
ventilation
127,076–249,695 104,544–194,614
Total cost: Noninvasive
ventilation
111,276–243,495 101,248–191,317
CAP-HR, community-acquired pneumonia-high risk; PF, profes-
sional fee; PHP, Philippine peso.
* Real prices, base year ¼ 2012.CAP-MR and CAP-HR. It estimated the health care cost for CAP-
MR to be in the range of about PHP25,000 to about PHP90,000,
whereas for CAP-HR, the estimates ranged from about PHP93,000
to a little less than PHP214,000. The wide range of monetary
values reﬂects variations in parameters that were considered in
the analysis, with the lowest value assuming the lowest cost
among the cost centers and the highest assuming the most
expensive. In the real-world scenario, the most sensitive may
be nearest the lowest value, considering that those in the higher
socioeconomic status (classes A–C) are just about 4% to 10% of
the population, while 64% to 70% are in class D and 22% to 28% in
class E [16]. In view of these, the patients or their families will try
to use the lowest possible diagnostic or treatment options
available to them.
Even if the estimated health care costs are those of the lowest
cost, this is still in striking contrast to case rate payments
mandated by PhilHealth for pneumonia. As demonstrated by
the results, the cost of IV antibiotics, especially for CAP-HR, was
tremendous such that PhilHealth’s case rate payment will not be
able to cover even 50% of the antibiotic cost alone. In addition,
the cost of ventilation, whether the invasive type or the non-
invasive type, was also relatively high, such that this cost alone
may have already consumed almost 100% of the case rate pay-
ment for CAP-HR. Hence, for patients with CAP-MR, the case rate
payment may cover only about 15% of the total cost of CAP-HR.
This means that the patient or his or her family needs to
shoulder a huge co-payment unless he or is fortunate to have a
private insurance (health maintenance organization) or is
employed in a company that provides for the health care cost
of its employees.
Some may argue that the huge cost obtained in this study
could be due to the private nature of the hospitals included in the
study. As demonstrated in the costing results, however, the cost
of hospitalization was largely driven by the cost of antibiotics,
which were not inﬂuenced by the study setting. As mentioned
earlier, the cost for the medicines was obtained from the biggest
drugstore chain, the prices of which are usually used as the
benchmark of other drugstores or hospital pharmacies in the
country. In addition, in a previous study carried out to calculate
the cost of acute coronary syndrome, the increment in the
hospital charges of one of the hospitals included in the study
was about 5.4% to 7.8% compared with that of a tertiary govern-
ment hospital located in Manila for patients admitted in either
ward or private room [8].
However, the cost reported in this study may even be under-
estimated because many of the patients have concomittant con-
ditions, necessitating additional diagnostic procedures and
treatment. In addition, other miscellaneous charges may not have
been added to the computation of the cost, further underestimat-
ing the cost. Last, the total economic burden of CAP-MR and
CAP-HR reported in this study entailed only those with Phil-
Health coverage. Considering that as of the end of 2012, PhilHealth
Fig. 1 – Hospitalization cost for (A) CAP-MR and (B) CAP-HR.
Table 5 – Postdischarge cost (PHP).*
Cost Hospital A Hospital B
CAP-MR
Out-of-pocket expenses 300–600 300–500
Production losses 950–7,600 950–7,600
Cost of consumption of
other resources
300–600 200–500
Total cost for CAP-MR 1,550–8,800 1,450–8,600
CAP-HR
Out-of pocket expenses 566–2,329 566–2,229
Production losses 950–7,600 950–7,600
Cost of consumption of
other resources
300–600 200–500
Total cost for CAP-HR 1,816–10,529 1,716–10,329
CAP-HR ¼ community-acquired pneumonia-high risk; CAP-MR,
community-acquired pneumonia-moderate Risk; PHP,
Philippine peso.
* Real prices, base year ¼ 2012.
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likely that some patients who were conﬁned for CAP-MR and CAP-
HR did not have PhilHealth coverage, resulting in the under-
estimation of the economic burden of pneumonia. Ironically, for
2013, PhilHealth’s estimated coverage went down to 79% of the
projected population. In contrast, the prevalence of CAP-MR and
CAP-HR as reﬂected in the number of claims went up by almost
43% for CAP-MR (495,745 claims from 347,653 claims) and more
than 100% for CAP-HR (15,254 from 7153 claims) [15,17].
Equity and Policy Implications in PhilHealth’s Case Rate
Payments
The article has shown that PhilHealth case rate payments for
CAP-MR covered approximately 17% to 61% of the estimated total
hospitalization cost (these percentages corresponded to the high-
est to the lowest estimated cost). For CAP-HR, the coverage was
approximately 15% to 35% of the hospitalization cost. However,
only about 31% of the study population had private health
insurance or health beneﬁts provided by their employer. This
meant that the large percentage of the hospitalization cost that
was not covered by PhilHealth needed to be shouldered by the
patient or his or her family. This is more apparent for cases of
CAP-HR whereby the PhilHealth pneumonia case rate will not besufﬁcient to even cover the cost of ventilatory support or the full
course of the IV antibiotics.
Table 6 – Type of payment.
Study Site Self-pay HMO Company Total number of patients
Hospital A 171 (35.4) 71 (14.7) 30 (6.2) 272 (56.3)
Hospital B 162 (33.5) 49 (10.1) 0 (0) 211 (43.7)
Total (%) 333 (68.9) 120 (24.9) 30 (6.2) 483 (100)
Note. Values are n (%).
HMO, health maintenance organization.
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considering that the average annual family income in 2012 was
only PHP235,000 [18]. Those in higher socioeconomic conditions
can afford to shoulder the costs not covered by PhilHealth;
however, this is not the case for those in lower socioeconomic
conditions where the needed personal funds are not available.
Some families would opt to discontinue medical care and just
bring the patient home even if the patient faced fatal consequen-
ces. However, those in the middle class may afford to cover the
additional costs by availing loans or using funds intended for
other purposes, for example, funds for their children’s education.
In a move to support the medical needs of “marginalized”
Filipinos, the government recently implemented a policy known
as “no balance billing.” This means that PhilHealth members who
are enrolled under the sponsored program (this program covers
indigents belonging to the lowest 25% of the population and
represents 31% of PhilHealth members) will not incur out-of-
pocket expenses if hospitalized for some speciﬁc diseases (which
include pneumonia) in government hospitals [17,19,20]. Phil-
Health, in turn, will pay the speciﬁc case rates to the government
hospital where the patient was conﬁned. This means that the
large difference in the actual cost of hospitalization (especially for
CAP-HR) compared with PhilHealth case rates would have to be
written off as losses by the hospitals, or else have to be sourced
elsewhere (e.g., charitable institutions). In addition, there is an
assumption that the government hospital always has the
capacity to provide the needed antibiotics and machines for
ventilatory support at all times, but this in reality may not be
possible.
The above estimates of hospitalization cost can be used by
stakeholders to negotiate for a bigger case rate payment from
PhilHealth for pneumonia. A positive response from PhilHealth
will, in turn, result in a bigger budget allocation for pneumonia.
Moreover, other stakeholders for other diseases may also want to
negotiate for higher coverage citing the same reason, that is, the
signiﬁcant disparity in PhilHealth’s coverage and the estimated
hospitalization cost. Increases in coverage rates, however, can be
met only by an increase in PhilHealth’s budget, which, in turn,
will necessitate the collection of higher premiums from its
members.Conclusions
The article reported the hospitalization and follow-up costs of
CAP-MR and CAP-HR based on the societal perspective. It showed
signiﬁcant disparity from the current PhilHealth case rate pay-
ments. The 2012 Philippine economic burden for CAP-MR and
CAP-HR was estimated at PHP8.48 billion and PHP643.76 million,
respectively, which may be an underestimation.Limitations
The prevalence of CAP-MR and CAP-HR depended on the number
of PhilHealth claims, which may not reﬂect their true prevalencebecause of the less than 100% PhilHealth coverage of the
country’s population.
Also, the available data from the Department of Health are for
the year 2009 [2]. Moreover, the data do not contain information
on the age group and the type of pneumonia and combine
pneumonia cases with other acute lower respiratory tract
infections.
The sensitivity analysis performed in the study was also
limited by the fact that it cannot cover all the possible scenarios
or models. An example is the assumption regarding the loss of a
day’s wage when someone accompanies the patient for his or her
follow-up visit after being discharged from the hospital. It may
happen that the accompanying person may still be able to report
for half a day, resulting in a decrease in the follow-up cost.
Last, modeling in health economic evaluations uses probabil-
istic sensitivity analysis “to reﬂect the uncertainty in the input
parameters of the decision model and describe what this means
for uncertainty over the outputs of interest: measures of cost,
effect and cost-effectiveness” [21]. This study, however, did not
use probabilistic sensitivity analysis. This cost analysis study
only considered the assumptions of possible lowest to the high-
est range of the identiﬁed cost centers.Acknowledgments
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